Clinical outcomes | With adverse events (n = 150) | Without adverse events (n = 119) | Unadjusted analysis | Multi-adjusted analysisa | ||
---|---|---|---|---|---|---|
HR/ORb (95% CI) | P valuec | HR/OR (95% CI) | P valued | |||
Median overall survival (IQR), days | 169 (96–255) | 103 (58–201) | 0.67 (0.51,0.88) | 0.0039 | 0.64 (0.48,0.84) | 0.001 |
Median progression-free survival (IQR), days | 86.5 (57–150) | 62 (41–121) | 0.75 (0.58,0.98) | 0.0309 | 0.69 (0.53,0.91) | 0.007 |
Disease control rate, n (%) | 82 (54.67) | 39 (32.77) | 2.47 (1.46,4.21) | < 0.001 | 2.67 (1.59,4.47) | < 0.001 |
Objective response rate, n (%) | 11 (7.33) | 6 (5.04) | 1.49 (0.49.5.06) | 0.443 | 1.42 (0.50,4.01) | 0.505 |